Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration

Neurobiology of Aging

Volumn 32, Issue 11, 2011, Pages 2100-2102

  Shin, Masahiro ^a,b   Jan, Caroline ^a   Jacquard, Carine ^a   Jarraya, Béchir ^a   Callebert, Jacques ^c   Launay, Jean Marie ^c   Hantraye, Philippe ^a   Remy, Philippe ^a,b   Palfi, Stéphane ^a,b   Brouillet, Emmanuel ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Motor deficits; Mouse model; MPTP; Parkinson's disease; Proteasome

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PROTEASOME INHIBITOR; UBIQUITIN;

AKINESIA; ANIMAL EXPERIMENT; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; IMMUNOREACTIVITY; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY; STRIATONIGRAL DEGENERATION; TREMOR; WEIGHT REDUCTION;

ANIMALS; CORPUS STRIATUM; CYSTEINE PROTEINASE INHIBITORS; HYPOKINESIA; MICE; MOTOR ACTIVITY; NEURONS; OLIGOPEPTIDES; SUBSTANTIA NIGRA;

EID: 80052618250     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.11.015     Document Type: Article

References (10)

1. Bové J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.-C., Kordower J.H. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 2006, 60:260-264.
2. Hirst S.J., Ferger B. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice. Synapse 2008, 62:85-90.
3. Kadoguchi N., Umeda M., Kato H., Araki T. Proteasome inhibitor does not enhance MPTP neurotoxicity in mice. Cell. Mol. Neurobiol. 2008, 28:971-979.
4. Kordower J.H., Kaanan N.M., Chu Y., Babu R.S., Stansell J., Tepstra B.T., Sortwell C.E., Steece-Collier K., Collier T.J. Failure of proteasome inhibitors to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 2006, 60:264-268.
5. Landau A.M., Kouassi E., Siegrist-Johnstone R., Desbarats J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov. Disord. 2007, 22:403-407.
6. Manning-Boĝ A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., Langston J.W., Di Monte D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 2006, 60:256-260.
7. Mathur B.N., Neely M.D., Dyllick-Brenzinger M., Tandon A., Deutch A.Y. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007, 1168:83-89.
8. McNaught K.S.P., Perl D.P., Brownell A.-L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
9. Schapira A., Cleeter M.W.J., Muddle J.R., Workman J.M., Cooper J.M., King R.H.M. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 2006, 60:253-255.
10. Zeng B.-Y., Bukhatwa S., Hikima A., Rose S., Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 2006, 60:248-252.